Pelage Pharmaceuticals Company Profile

Pelage Pharmaceuticals develops regenerative medicine treatments for hair loss grounded in stem cell biology. Its lead candidate, PP405, is a topical small molecule designed to modulate metabolic signaling in hair follicle stem cells, reactivating dormant follicles instead of masking symptoms, and it is being studied for androgenetic alopecia in women as well as men.

Based in Westwood, Los Angeles and led by chief executive Daniel Gil and cofounder William Lowry, Pelage completed a Phase 2 study on the strength of roughly $34 million in prior funding before raising a $120 million round in October 2025 to advance PP405 toward FDA conversations, and the treatment was named among Time's Best Inventions of 2025.

Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Pelage Pharmaceuticals.

Often trade at a premium or discount to NAV.

Platforms match existing holders with buyers. Pelage Pharmaceuticals availability at any moment is set by the holders.

High minimums, transfer approval, company right-of-first-refusal.

Valuations, rounds and IPO status for every company in the directory — Pelage Pharmaceuticals included.

No. Pelage Pharmaceuticals is a private company; its shares do not trade on a public exchange.

Lead investors for each round are in the funding timeline.

The closest biotechnology & pharmaceuticals peers are on the competitors page.

The routes section explains what is realistically available for a company at this stage.